Odyssey Therapeutics Extends Financial Runway to 2028 as Clinical Trials Expand
Odyssey Therapeutics (NASDAQ:ODTX) reported $433.1 million in cash reserves on June 30, 2026, providing a financial runway through the second half of 2028. This allows the company to advance its pipeline without needing immediate additional capital raises. The firm is preparing for an October data presentation at United European Gastroenterology Week and plans two new trials with OD-001 before year-end. The clinical progress includes a Phase 2a expansion cohort completed, while OD-002 moves toward a clinical trial application by the end of 2026. Despite growing R&D spending that pushed Q2 net losses to $52.8 million from $41.2 million in the prior year, adjusted net loss remained nearly flat at $38.4 million. Institutional interest has increased sharply with hedge fund ownership rising to 24 funds compared to zero previously, while short sellers maintain a stake of 5.25%. The October data readout is seen as critical for shifting investor sentiment.
Tickers: $ODTX
Topics: biopharmaceutical cash runway pipeline progress RIPK2 inhibitor